Disproportionality analysis of oesophageal toxicity associated with oral bisphosphonates using the FAERS database (2004-2023).

ABSTRACT:

Background

This study analyzed the FDA's Adverse Event Reporting System (FAERS) data to investigate the correlation between oral bisphosphonates (BPs) and oesophageal adverse events (AEs).

Methods

We systematically extracted data on adverse reactions to oral alendronate, risedronate, and ibandronate from the FAERS database, covering the period from the 2004 Q1 to the 2023 Q4. The role_code of AEs mainly includes primary suspect (PS), secondary suspect (SS), concomitant (C), and interaction (I). This study targeted reports with a role_code of "PS." According to the FDA deduplication rule, the latest FDA_DT is selected when the CASEID is the same, and the higher PRIMARYID is selected when the CASEID and FDA_DT are the same. Our analysis leveraged four statistical methods, incl

SUBMITTER: Chen L 

PROVIDER: S-EPMC11578700 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature